1. Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center. Issue 4 (August 2018) Authors: Afzal, Muhammad Z.; Shirai, Keisuke Journal: Melanoma research Issue: Volume 28:Issue 4(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Nicorandil, a Nitric Oxide Donor and ATP-Sensitive Potassium Channel Opener, Protects Against Dystrophin-Deficient Cardiomyopathy. (November 2016) Authors: Afzal, Muhammad Z.; Reiter, Melanie; Gastonguay, Courtney; McGivern, Jered V.; Guan, Xuan; Ge, Zhi-Dong; Mack, David L.; Childers, Martin K.; Ebert, Allison D.; Strande, Jennifer L. Journal: Journal of cardiovascular pharmacology and therapeutics Issue: Volume 21:Number 6(2016:Nov.) Page Start: 549 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors. Issue 7 (September 2019) Authors: Afzal, Muhammad Z.; Sarwar, Tayyaba; Shirai, Keisuke Journal: Journal of immunotherapy Issue: Volume 42:Issue 7(2019:Sep.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab. Issue 4 (May 2019) Authors: Afzal, Muhammad Z.; Shirai, Keisuke Journal: Journal of immunotherapy Issue: Volume 42:Issue 4(2019:May) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗